EUVIMEDEUVIMED entdecken
Crossref

Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole

Kazuo Maeda

Archives of Clinical Case Studies · 2019

DOI: 10.33552/accs.2019.01.000513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Clinical Case Studies, 2019. Verfasst von Kazuo Maeda.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The author treated choriocarcinoma (Ch-C) with systemic primary Methotrexate (MTX) and achieved complete remission with the disappearance of primary and metastatic foci by repeated 200 to 300 mg intensive MTX courses, confirmed by the loss of human chorionic gnadotropine (hCG) in the serum and urine. Thus, the author intended to prevent choriocarcinoma (Ch-C) with MTX chemotherapy.

Zitieren

APA

Maeda, K. (2019). Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole. Archives of Clinical Case Studies. https://doi.org/10.33552/accs.2019.01.000513

Vancouver

Maeda K. Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole. Archives of Clinical Case Studies. 2019. doi:10.33552/accs.2019.01.000513

BibTeX
@article{Maeda2019,
  author = {Maeda, Kazuo},
  title = {Chemotherapeutic Prevention of Choriocarcinoma Developed in Persistent Trophoblastic Disease after Hydatidiform Mole},
  journal = {Archives of Clinical Case Studies},
  year = {2019},
  doi = {10.33552/accs.2019.01.000513}
}
Kostenlos starten →